Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jun 24, 2015
Insider Transaction Report
Form 4
Stolz Brian M.
EVP, Administration and CHCO
Transactions
- Tax Payment
Common Stock, no par value
2015-06-22+2,292→ 125,280 total
Footnotes (3)
- [F1]This number represents common shares ("Common Shares") of Valeant Pharmaceuticals, Inc. ("Valeant") withheld to satisfy the tax withholding obligations due upon vesting of performance-based RSUs.
- [F2]This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II. See note (3).
- [F3]The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $51.76 starting on August 10, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on May 10, 2014, 50% August 10, 2014 and 25% on November 10, 2014 (or 25% on May 10, 2015, 50% on August 10, 2015 and 25% on November 10, 2015, if applicable). Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs remain unvested for up to 29,044 Common Shares.